Selection of PPI in a comorbid patient with NSAIDgastroesophagopathy: case study
https://doi.org/10.21518/2079-701X-2019-3-48-54
Abstract
About the Author
I. G. PakhomovaRussian Federation
Cand. of Sci. (Med.), Associate Professor of Ryss Chair of Propaedeutics of Internal Diseases, Gastroenterology and
Dietary Science,
191015, St. Petersburg, Kirochnaya St., 41
References
1. Comorbid pathology in clinical practice. Clinical guidelines. Kardiovaskulyarnaya Terapiya i Profilaktika. 2017;16(6):5-56.
2. Верткин А.Л., Румянцев М.А., Скотников А.С. Коморбидность. Клиническая медицина. 2012;10:4–11.
3. Губанова Г.В., Беляева Ю.Н., Шеметова Г.Н. Коморбидный пациент: этапы формирования, факторы риска и тактика ведения. Современные проблемы науки и образования. 2015;6:1-7.
4. Statistical Office of the European Union (Eurostat), Ageing Report, World Health Organization, 10/01/2015.
5. Lazebnik L.B. Polymorbidity in the elderly. Serdtse. 2007;7:25-27.
6. Karateev A.E., Nasonov E.L. The use of nonsteroidal antiinflammatory drugs in rheumatic diseases. Russian clinical guidelines. Rheumatology. Under the editorship of E.L. Nasonov. M.: GEOTAR-Media, 2017:339-359.
7. Guidelines for the prevention and treatment of esophagogastroenterocopathy induced by nonsteroidal anti-inflammatory drugs (NSAIDs). Eksperimentalnaya i Kliniches kaya Gastroenterologiya. 2018;3(151):4-18.
8. Lanas A., García-Rodríguez L.A., Polo-Tomás M. et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol. 2009;104:1633–1641.
9. Abraham N.S., Noseworthy P.A., Yao X. et al. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2017;152:1014–1022.
10. Pakhomova I.G. New opportunities for reducing the risk of NSAID-induced gastropathy. RMJ. 2014;10: 772–776
11. Juurlink D.N., Gomes T., Ko D.T. et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713-718.
12. Bardou M., Martin J. Pantoprazole: from drug metabolism to clinical relevance. Expert Opin Drug Metab Toxicol. 2008;4:471-483.
13. Blume H., Donath F., Warnke A., Schug B. S. Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors. Drug Safety. 2006;29(9):769-784.
14. Robinson M., Horn J. Clinical pharmacology of proton pump inhibitors. Drugs. 2003;63: 2739-2754.
15. Brunner G., Athmann C., Schneider A. Long-term, open-label trial: safety and efficacy of continuous maintenance treatment with pantoprazole for up to 15 years in severe acid-peptic disease. Aliment Pharmacol Ther. 2012;36(1):37–47.
16. Altman R., Barthel H. Topical therapies for osteoarthritis. Drugs. 2011;9,71(10):1259-1279.
Review
For citations:
Pakhomova IG. Selection of PPI in a comorbid patient with NSAIDgastroesophagopathy: case study. Meditsinskiy sovet = Medical Council. 2019;(3):48-54. (In Russ.) https://doi.org/10.21518/2079-701X-2019-3-48-54